Oral Cancer

P=N/A, N=30, Recruiting, Tishreen University

P=N/A, N=28, Recruiting, Damascus University

To our knowledge, this is the first comprehensive MR study linking sex hormone-related factors (E2, EST, BCAR3) to increased oral cavity cancer risk. Further validation is needed to explore prevention and treatment implications.

The effects of Maackia amurensis seed lectin and SRY-box transcription factor 2 on oral squamous cell carcinoma cells were determined via Cell Counting Kit-8 and colony formation assays.ResultsThe results demonstrated that increased expression of SRY-box transcription factor 2 in oral squamous cell carcinoma is correlated with elevated levels of N6-methyladenosine modification, and treatment with Maackia amurensis seed lectin reduces the N6-methyladenosine modification level and SRY-box transcription factor 2 expression. Moreover, overexpression of SRY-box transcription factor 2 reversed the inhibitory effects of Maackia amurensis seed lectin on oral squamous cell carcinoma cell proliferation and colony formation.ConclusionsMaackia amurensis seed lectin may inhibit oral squamous cell carcinoma cell proliferation by suppressing N6-methyladenosine modification-mediated SRY-box transcription factor 2 expression, thereby improving chemotherapy sensitivity in oral squamous cell carcinoma.

In this study, we observed that EP300 knockdown suppressed the Notch signaling pathway, consequently inhibiting OSCC cell proliferation, the cell cycle, and EMT while also promoting apoptosis. These findings suggest that EP300 is crucial for OSCC cell growth and development.

EIF3B activated PI3K/AKT signaling and EMT, both of which were abolished by miR-124-3p or LY294002. These findings define the miR-124-3p/EIF3B/PI3K-AKT axis as a key regulator of OSCC progression and suggest EIF3B as a potential prognostic biomarker and therapeutic target.

P=N/A, N=56, Recruiting, Alpha Tau Medical LTD. | Trial completion date: Jan 2026 --> Jul 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

P=N/A, N=33, Recruiting, Centre Hospitalier Universitaire, Amiens | N=14 --> 33 | Trial completion date: Oct 2023 --> Oct 2026 | Trial primary completion date: Oct 2023 --> Oct 2026

Interpretation and conclusion Our study revealed that SPHK1 expression is upregulated through HIF-1α, which in turn stabilises HIF-2α. Thus, inhibition of SphK1 along with HIF-2α might be beneficial for the management of OSCC.

In vivo analysis confirmed target engagement (NUDT21-down) and functional restoration (PTEN-, WEE1-, TGF-β-up). This work validates a "post-transcriptional re-engineering" strategy, executed by a logically designed nanoplatform, as a powerful and safe modality for precision gene therapy.

P1, N=67, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed

Current oral cancer pain management strategies, including opioids, are inadequate and are burdened by unacceptable side effects. By abrogating the actions of growth factors, including NGF, NRP1-targeted therapies represent an alternative approach to mitigate cancer pain and possibly slow tumor growth.